60 Degrees Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for the prevention and treatment of infectious diseases. Its commercial portfolio centers on Arakoda, a malaria prevention therapy, while its broader pipeline includes tafenoquine-based programs and other candidates being studied for vector-borne, fungal, and viral infections. The company works across areas such as malaria, babesiosis, respiratory infections, and dengue, reflecting a research strategy aimed at diseases with significant unmet medical need. 60 Degrees Pharmaceuticals Inc. serves as a niche biotechnology player in the healthcare market, combining product commercialization with ongoing clinical development. Headquartered in Washington, D.C., the company also maintains operations linked to research and collaboration in Australia.
Website1025 Connecticut Avenue NW
Washington, DC, 20036
United States
– On-demand company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET – – Management will be available for one-on-one investor meetings during the conference – WASHINGTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, today announced that management will participate in the H.C. Wainwright 28th Annual
Detailed price information for 60 Degrees Pharmaceuticals Inc (SXTP-Q) from The Globe and Mail including charting and trades.
WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported today its financial results for the second quarter of 2026, ended June 30, 2026. Financial Highlights for the Quarter Ended June 30, 2026: Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026, from approximately $101 thousand
Detailed price information for 60 Degrees Pharmaceuticals Inc (SXTP-Q) from The Globe and Mail including charting and trades.
Investors talking about SXTP also mention
What share of all stock conversation is about SXTP?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% +0 | 0% +0 | 0% 0 | 0% 0 |
Of the messages about SXTP that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 100% | 100% 0 | 100% 0 | 83.55% -0.89 | ||
| Bearish | 0% | 0% 0 | 0% 0 | 16.45% +0.89 |
Of the messages about SXTP that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | 0% | 75% | 91.67% | 45.98% | ||
| Technical Analysis | 100% | 25% | 8.33% | 24.37% | ||
| Analysts | 0% | 0% | 0% | 9.88% | ||
| Controversies | 0% | 0% | 0% | 0% | ||
| Earnings | 0% | 0% | 0% | 0% | ||
| Macro | 0% | 0% | 0% | 19.77% |
Of the messages about SXTP, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 100% | 81.25% | 83.87% | 17.76% | ||
| Newcomers | 0% | 18.75% | 16.13% | 82.24% |